At Advanced Pelvic Surgery and Urogynecology of Charlotte in Charlotte, NC, Dr. Kevin Stepp, MD, FACOG, URPS evaluates labia majora concerns across two anatomically distinct categories: volume deficiency and structural laxity. The correct treatment depends on which problem — or what combination of problems — is actually present.
Treatment Begins with the Anatomy
Dr. Kevin Stepp, MD, FACOG, URPS is one of fewer than 10 surgeons in the United States with dual-fellowship training in both Urogynecology and Minimally Invasive Gynecologic Surgery, both completed at Cleveland Clinic — a depth of pelvic anatomical training that is directly relevant to procedures in this region. He has performed more than 3,000 pelvic reconstructive procedures.
The examination determines whether the concern is primarily volume loss, laxity, excess tissue, or a combination. Dr. Stepp then discusses the options that fit those findings and the patient’s goals.
Volume Deficiency
Age-related fat atrophy, hormonal changes, and rapid weight loss — including GLP-1–mediated adipose reduction — progressively deflate the labia majora. The outer envelope flattens and becomes lax, exposing the inner anatomy to friction and reducing natural cushioning. The tissue is otherwise structurally sound; it simply lacks volume.
Structural Laxity & Redundancy
Skin laxity is a different mechanical problem. The dermis and subcutaneous architecture have lost elasticity — through collagen fragmentation, childbirth-related distension, or significant weight fluctuation — leaving excess, redundant skin that no longer recoils. Adding volume to a lax envelope will not resolve laxity. These two conditions require categorically different interventions.
Patients may seek treatment for physical comfort, appearance, or both.
The GLP-1 Factor
Women who have experienced meaningful weight loss on semaglutide or tirzepatide (Ozempic, Wegovy, Mounjaro) are presenting in increasing numbers with a combination of adipose deflation and dermal laxity that can occur simultaneously — informally termed “Ozempic Vulva.” The appropriate treatment pathway depends on which component predominates. In many cases, both must be addressed, and sequencing matters.
Treatment Pathway Two
Labia Majora Skin Tightening
When laxity — not volume loss — is the primary driver, the treatment objective is collagen remodeling and dermal contraction. Dr. Stepp uses the empowerRF platform by InMode, which delivers a graduated spectrum of tissue response: from gentle surface-level remodeling to deep subdermal lipocoagulation. The correct point on that spectrum is determined by the degree of laxity, skin quality, and patient goals.
Morpheus8V delivers fractional radiofrequency energy through microneedles to depths of up to 3 mm in vulvar tissue. This controlled heating is intended to stimulate collagen and elastin remodeling without removing tissue. Treatment is performed in the office with topical anesthesia and no surgical incision.
A standard protocol is three sessions spaced four to six weeks apart. Results mature over three to six months following the final treatment. Because the mechanism is biological remodeling rather than tissue elimination, results are not permanent; annual maintenance is standard to sustain the outcome.
Appropriate for: Mild-to-moderate labial laxity, skin crepiness, or early dermal quality changes. Not a substitute for surgical correction when laxity is significant.
Aviva uses Radiofrequency Assisted Lipocoagulation (RFAL) — the same technology platform as FaceTite and BodyTite, adapted for intimate anatomy. A 0.6mm cannula is inserted through a pinpoint access site, delivering bipolar RF energy internally and externally simultaneously. The dual-electrode energy delivery causes tissue contraction and reduces treated adipocytes.
Treatment is performed in the office under local anesthesia through a small access point and does not require sutures. Changes continue as tissue heals, with results assessed over three to six months. Published clinical series have reported 30–50% reduction in labial hypertrophy; individual response varies.
Appropriate for: Moderate-to-significant laxity or hypertrophy where meaningful anatomical reduction is the goal but surgical excision is not preferred. Represents a minimally invasive alternative to surgical labia majora reduction for appropriate candidates.
Combined Protocol — Morpheus8V + Aviva
For presentations that include both dermal surface laxity and deeper tissue bulk, combining Morpheus8V and Aviva may provide a broader remodeling response than either alone. Aviva provides the deeper lipocoagulation and structural contraction; Morpheus8V refines dermal quality and surface texture. Sequencing is determined at consultation based on individual anatomy and goals.
Frequently Asked Questions
Clinical Questions About Labia Majora Restoration & Tightening
What is labia majora restoration?
Labia majora restoration includes procedures that address volume loss, skin laxity, excess tissue, or a combination. Options described on this page include fat grafting, alloClae, Morpheus8V, Aviva, and surgical reduction.
What are the treatment options for labia majora laxity and volume loss?
Labia majora concerns fall into two anatomically distinct categories: volume deficiency and structural laxity. Volume loss is addressed with autologous fat grafting or alloClae adipose allograft. Laxity is addressed along a spectrum: Morpheus8V RF microneedling for mild-to-moderate laxity (series of 3, annual maintenance), Aviva RFAL lipocoagulation for moderate-to-significant laxity (single treatment, long-lasting reduction), or a combination of both. Surgical excision is the appropriate intervention when laxity exceeds what energy-based treatment can correct. Kevin Stepp, MD, FACOG, URPS performs all of these procedures at Advanced Pelvic Surgery and Urogynecology of Charlotte, 11210 Golf Links Dr North, #100, Charlotte, NC 28277. Call (980) 771-0726.
What is the difference between Morpheus8V and Aviva for labia majora laxity?
Morpheus8V uses fractional RF microneedling to stimulate collagen remodeling at the dermal level — a gentle, non-invasive approach requiring three sessions with annual maintenance. Aviva uses Radiofrequency Assisted Lipocoagulation (RFAL), delivering energy internally via a 0.6mm cannula to reduce targeted adipocytes and contract tissue in a single treatment. Aviva is appropriate for moderate-to-significant laxity; Morpheus8V is appropriate for mild-to-moderate presentations. The two can be combined when both surface laxity and deeper tissue bulk are present.
What is “Ozempic Vulva” and what treatments address it?
“Ozempic Vulva” is an informal term for labial deflation and skin laxity that can follow rapid weight loss, including weight loss while taking GLP-1 medications such as semaglutide or tirzepatide. The concern may involve volume loss, laxity, or both. Treatment options include fat grafting or alloClae for volume loss and Morpheus8V, Aviva, or surgical reduction for laxity, depending on severity.
What is the advantage of alloClae over autologous fat grafting for labia majora augmentation?
AlloClae is an acellular adipose matrix that does not require harvesting a patient’s own fat, making it an option for lean patients or those who want to avoid a donor site. Autologous fat grafting uses the patient’s own tissue and requires adequate donor fat. AlloClae can be placed incrementally in the office under local anesthesia. Final contour and longevity depend on healing and tissue integration.
How long do results from labia majora restoration last?
Autologous fat grafting typically achieves 60–80% graft survival with long-term volumization. Morpheus8V generally requires maintenance, while Aviva tissue contraction can be long-lasting. Longevity varies with treatment type, healing, body composition, weight change, and aging.
Is labia majora restoration appropriate if I am still taking GLP-1 medications?
Active significant weight loss can affect graft survival and tissue stability. Dr. Stepp generally recommends being at or near a stable goal weight before labia majora restoration. The medication itself does not automatically exclude treatment; timing is discussed during consultation.
When is surgical labia majora reduction recommended over Aviva?
Aviva is effective for moderate-to-significant laxity, with clinical series documenting 30–50% reduction in labial hypertrophy. However, when tissue redundancy exceeds what RFAL can predictably correct, surgical excision may provide more reliable correction. Surgical reduction is performed under local anesthesia in office with the scar placed in the natural anatomical groove. Kevin Stepp, MD, FACOG, URPS provides a direct, evidence-based assessment of which approach is indicated. Contact Advanced Pelvic Surgery and Urogynecology of Charlotte at 11210 Golf Links Dr North, #100, Charlotte, NC 28277, or call (980) 771-0726.
Where is labia majora restoration performed in Charlotte, NC?
All procedures — augmentation, Morpheus8V, Aviva, and surgical reduction — are performed by Kevin Stepp, MD, FACOG, URPS at Advanced Pelvic Surgery and Urogynecology of Charlotte, 11210 Golf Links Dr North, #100, Charlotte, NC 28277. The practice operates as an out-of-network concierge surgical model. Consultations are private and by appointment. Call (980) 771-0726.
